<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851640</url>
  </required_header>
  <id_info>
    <org_study_id>HC-1119-04</org_study_id>
    <nct_id>NCT03851640</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Failed Treatments With Abiraterone Acetate and Docetaxel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hinova Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hinova Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study primary objective is to evaluate the effect of HC-1119 soft capsules versus placebo&#xD;
      on overall survival (OS) in mCRPC patients who have failed or become intolerant to the&#xD;
      treatments with both abiraterone acetate and docetaxel, or who are not suitable for docetaxel&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From baseline until death from any cause (up to approximately 30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival (rPFS)</measure>
    <time_frame>From signing informed consent up to approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>From signing informed consent up to approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From signing informed consent up to approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From signing informed consent up to approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of prostate specific antigen (PSA)</measure>
    <time_frame>From signing informed consent up to approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to prostate specific antigen(PSA) progression (TTPP)</measure>
    <time_frame>From signing informed consent up to approximately 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>From signing informed consent up to approximately 30 months</time_frame>
    <description>Safety measures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>mCRPC</condition>
  <arm_group>
    <arm_group_label>HC-1119</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mg;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>80mg;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HC-1119</intervention_name>
    <description>oral</description>
    <arm_group_label>HC-1119</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males aged ≥18 years at screening and voluntary to participate in the study and sign&#xD;
             the informed consent form.&#xD;
&#xD;
          2. Subjects with histologically or cytologically confirmed prostate adenocarcinoma, with&#xD;
             no small cell features.&#xD;
&#xD;
          3. In the case of medical or surgical castration, during or after the last treatment&#xD;
             before screening, there are signs of progressive disease determined according to the&#xD;
             PCWG3 criteria, defined as satisfying one or more of the following 3 criteria:&#xD;
&#xD;
               1. PSA progression; at least 2 episodes of increased PSA levels that are measured ≥1&#xD;
                  week apart; PSA ≥ 1 μg/L (1 ng/mL) in the screening period;&#xD;
&#xD;
               2. Progression of soft tissue lesions as defined by RECIST 1.1;&#xD;
&#xD;
               3. The progression of bone lesions is defined as at least two new lesions discovered&#xD;
                  by bone scan; ambiguous results can be confirmed using another imaging technique&#xD;
                  (e.g., CT or MRI).&#xD;
&#xD;
          4. Metastatic diseases confirmed by imaging examinations during the screening period (the&#xD;
             status of metastasis refers to the presence of metastatic lesions confirmed by bone&#xD;
             scan and/or CT/MRI scan).&#xD;
&#xD;
          5. For patients who have undergone orchiectomy or are being treated by medical castration&#xD;
             therapy, their androgen blockade therapy is maintained by luteinizing&#xD;
             hormone-releasing hormone agonists or antagonists during the study period (including&#xD;
             the follow-up period), and their serum testosterone levels are ≤ 1.73 nmol/L (50&#xD;
             ng/dL) during screening visits.&#xD;
&#xD;
          6. Patients who have failed previous treatments of prostate cancer with abiraterone&#xD;
             acetate or who are intolerant to treatments with abiraterone acetate.&#xD;
&#xD;
          7. Patients who have failed previous chemotherapy of prostate cancer with docetaxel or&#xD;
             who are intolerant to treatments with docetaxel, or who are not suitable for docetaxel&#xD;
             treatment during screening. Patients who are not suitable for docetaxel treatment&#xD;
             during screening and do not plan to use cytotoxic chemotherapy within 6 months after&#xD;
             the informed discussion are eligible.&#xD;
&#xD;
          8. Expected survival of ≥ 3 months.&#xD;
&#xD;
          9. ECOG performance status score of 0-2.&#xD;
&#xD;
         10. Laboratory tests must meet the following criteria:&#xD;
&#xD;
               1. Blood routine examination: Hemoglobin (Hb) ≥ 85 g/L; white blood cell (WBC) ≥ 3.0&#xD;
                  x 109/L; platelet (PLT) ≥ 75 x 109/L;&#xD;
&#xD;
               2. Liver function: Total bilirubin (TBIL) ≤ 1.5 x ULN; alanine aminotransferase&#xD;
                  (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN (for patients without&#xD;
                  liver metastasis) or ≤ 5 x ULN (for patients with liver metastasis); albumin&#xD;
                  (ALB) ≥ 25 g/L;&#xD;
&#xD;
               3. Renal function: serum creatinine (SCr) ≤ 1.5 x ULN.&#xD;
&#xD;
         11. Willing to use reliable contraceptive measures (such as condoms) and not to donate&#xD;
             sperms throughout the study period and within 3 months after the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with any of the following conditions should not be enrolled:&#xD;
&#xD;
          1. Received any anti-prostate cancer treatment within 4 weeks before randomization,&#xD;
             including chemotherapy, immunotherapy, targeted therapy, estrogen therapy,&#xD;
             anti-androgen therapy, systemic radiotherapy, treatments with traditional Chinese&#xD;
             medicines for anticancer, or treatments with interventional drugs of other clinical&#xD;
             trials; palliative radiotherapy or surgery for bone metastatic or soft tissue lesions&#xD;
             should be completed &gt;14 days prior to baseline imaging examinations; the lesions&#xD;
             treated by palliative radiotherapy should not be the targeted lesions of subsequent&#xD;
             RECIST 1.1 assessment. Androgen blockade therapy that is maintained by a luteinizing&#xD;
             hormone releasing hormone agonist or antagonist.&#xD;
&#xD;
          2. Previously received any of novel androgen receptor inhibitors (e.g., Enzalutamide,&#xD;
             Apalutamide, Darolutamide, SHR3680, Proxalutamide, or HC-1119).&#xD;
&#xD;
          3. Patients with brain or central nervous system metastases are known (if a brain or&#xD;
             central nervous system metastasis is suspected, a CT/MRI scan of the head is required)&#xD;
&#xD;
          4. Patients with known serious cardiovascular diseases, including any of the following:&#xD;
&#xD;
               1. A myocardial infarction or thrombotic event occurred in the past 6 months;&#xD;
&#xD;
               2. Known unstable angina;&#xD;
&#xD;
               3. Heart failure of Grade III or IV according to the New York Heart Association&#xD;
                  (NYHA) criteria;&#xD;
&#xD;
               4. QT interval of &gt; 500 ms during screening visits;&#xD;
&#xD;
               5. Resting systolic blood pressure of &gt;170 mmHg or diastolic blood pressure of &gt;105&#xD;
                  mmHg suggesting uncontrolled hypertension during screening visits.&#xD;
&#xD;
          5. The toxicity of previous treatment has not been eliminated before the start of the&#xD;
             study treatment; toxic reaction of grade 2 or above (except for hair loss) according&#xD;
             to the CTCAE 5.0 grading scale remains.&#xD;
&#xD;
          6. Clinically significant gastrointestinal abnormalities that may affect the intake,&#xD;
             transport or absorption of drugs (for example, inability to swallow, chronic diarrhea&#xD;
             or intestinal obstruction, and patients had total gastrectomy).&#xD;
&#xD;
          7. Patients with a history of serious diseases in the central nervous system. Patients&#xD;
             with a history of epilepsy or any history of diseases that may induce epilepsy,&#xD;
             including unexplained loss of consciousness or transient ischemic attack.&#xD;
&#xD;
          8. Patients who have been diagnosed in the past 5 years with other malignant tumors in&#xD;
             addition to prostate cancer, except patients with cured basal or squamous cell skin&#xD;
             cancer and superficial bladder tumors (Ta, Tis, and T1).&#xD;
&#xD;
          9. Patients with a history of allogeneic bone marrow or organ transplantation who require&#xD;
             continued medical treatment.&#xD;
&#xD;
         10. Patients with known congenital or acquired immunodeficiency, active hepatitis, active&#xD;
             tuberculosis or other active infections.&#xD;
&#xD;
         11. Patients known to be allergic to androgen receptor inhibitors.&#xD;
&#xD;
         12. The investigator believes that the patients are unfit for this study (e.g., the&#xD;
             treatments will not benefit the patients the most, inadequate patient compliance,&#xD;
             etc.).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhonghua Zhou</last_name>
    <phone>+862885058465</phone>
    <phone_ext>8006</phone_ext>
    <email>zhzhou1@hinovapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye DingWei</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 17, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

